In cooperation with the technical Bureau of the British Medical Research Council, Yabao Pharmaceutical (Shanghai Securities: 600351) jointly developed a kinase targeted innovative drug for the treatment of Parkinson's disease. On August 6, 2014, Yabao Pharmaceutical (Shanghai Securities: 600351) announced a strategic partnership with Changzhou Innolux Shengkang to jointly develop the PLK / PI3K dual target inhibitor ls-008 at the preclinical stage. This unique cooperation mode creatively uses the complementary advantages of the expertise of Chinese pharmaceutical enterprises and pharmaceutical chemistry and drug development institutions to accelerate the development of antitumor compounds in China.
According to the terms of the agreement, Yabao pharmaceutical obtained the development agency right and sales right of ls-008 in China, while Changzhou yinnuo Shengkang retained most of the rights in other markets. The two sides will jointly decide on the development strategic plan, which will be mainly implemented by Yabao under GLP, GMP and GCP standards. The financial terms have not been disclosed.
Dr. Wang Peng, President of Yabao pharmaceutical, said: "PLK / PI3K dual target inhibitor is a new type of cancer drug. At present, some drugs have entered the global phase III clinical development. We firmly believe that ls-008 will become a new drug. This breakthrough cooperation with Changzhou Innolux Shengkang is Yabao's commitment to bring drugs to severe patients all over the world through the application of science and technology and its own strong clinical and regulatory ability." Professor Wang Shudong, founder and President of Innolux Shengkang, said: "I am very happy to reach a cooperative relationship with Yabao, China's leading pharmaceutical company. Through cooperation, we are taking advantage of both sides to develop new drugs to help patients around the world“
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) As a Chinese pharmaceutical enterprise, Yabao has perfect capabilities in drug development, production and commercialization in China. Recently, Yabao has adjusted its strategic development direction and aimed at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities, and the production of preparations and APIs meets the quality management of drug production CGMP requirements and passed the inspection of FDA and EU drug regulatory authorities respectively.
About Changzhou yinnuo Shengkang
Changzhou Innolux Shengkang is a biopharmaceutical company that develops oral therapies for the treatment of cancers with different cell cycles. Professor Wang Shudong of the University of Australia is recognized in the field of kinase targeted drug chemistry and drug discovery, and the company was established in 2011. The company is developing several drug projects, including CDKs and various mitotic kinase targets. The company's strategy is to establish a foundation Pharmaceutical business based on new candidate drug development pipeline.
请将简历发送至：